PT-141 vs sildenafil: central desire vs peripheral blood flow
Two FDA-approved drugs for sexual dysfunction, targeting completely different mechanisms. Complement each other more than they compete.
PT-141 (bremelanotide, brand Vyleesi) and sildenafil (brand Viagra) are both FDA-approved treatments for sexual dysfunction — but they target entirely different components of the sexual-response system. Sildenafil is a PDE5 inhibitor that acts peripherally on vascular smooth muscle to support erectile function. PT-141 is a melanocortin receptor agonist that acts centrally on CNS pathways involved in sexual desire and arousal.
| Field | PT-141 (bremelanotide) | Sildenafil |
|---|---|---|
| Brand names | Vyleesi | Viagra, Revatio |
| Manufacturer | AMAG Pharmaceuticals (now Palatin Technologies) | Pfizer (and generics) |
| FDA approved | 2019 (HSDD in premenopausal women) | 1998 (erectile dysfunction); 2005 (pulmonary hypertension) |
| Indication | Hypoactive sexual desire disorder (premenopausal women) | Erectile dysfunction; pulmonary arterial hypertension |
| Mechanism | Melanocortin receptor agonist (central) | PDE5 inhibitor (peripheral vascular smooth muscle) |
| Delivery | On-demand subcutaneous injection (before sexual activity) | Oral tablet, on-demand |
Primary sources
- PT-141 (bremelanotide): Vyleesi RECONNECT Phase 3 (Obstetrics & Gynecology)
- Sildenafil: Sildenafil ED pivotal trial (NEJM)
Frequently asked
Can they be used together?
Theoretically yes — they act on different systems. PT-141's prescribing information cautions about cardiovascular considerations (transient blood pressure effects), so combining with sildenafil requires clinician input. The combination is not a standard prescribing pattern.
Why is PT-141 only approved for women?
The RECONNECT Phase 3 trials enrolled premenopausal women with HSDD; FDA approval mirrored the trial population. Development in men for ED preceded the women's program but wasn't pursued to approval. Off-label use in men occurs but isn't backed by large FDA-approved trials.
Which has worse side effects?
PT-141 has a meaningful side-effect profile: nausea (40% of users), flushing, temporary skin darkening (off-target MC1R activation), and transient blood pressure elevation. Sildenafil is generally well-tolerated with headache, flushing, and dyspepsia as common mild side effects. For most patients, sildenafil has the cleaner profile.